Society: AGA

Background and Aims: Peptostreptococcus stomatis (P. stomatis) is an enriched bacterium in colorectal cancer (CRC) patients as compared to healthy subjects in multiple cohorts. However, the potential role of P. stomatis in colorectal tumorigenesis remains obscure. In this study, we investigate the function of P. stomatis in CRC, and its impact on CRC therapy response.

Methods: Pro-tumorigenic effect of P. stomatis on colorectal carcinogenesis was determined in Apc^Min/+ mice and azoxymethane/Dextran sodium sulfate (AOM-DSS)-treated mice models. In vitro function of P. stomatis was analysed by cell proliferation, apoptosis, and cell cycle assays. Interplay between P. stomatis and CRC cells was evaluated by fluorescence in situ hybridization (FISH), scanning electron microscopy (SEM), transmission electron microscopy (TEM), adhesion and invasion assays. The interaction between P. stomatis surface protein and the receptor of CRC cells was investigated by far-western, biotin pulldown, and glutathione S-transferase (GST) pulldown assays.

Results: Oral gavage of P. stomatis significantly promoted CRC tumorigenesis in Apc^Min/+ mice with increased colon tumor number and tumor load, which accompanied with enhanced cell proliferation, reduced apoptosis and impaired gut barrier function. The pro-tumorigenic effect of P. stomatis was validated in another CRC tumorigenesis model induced by AOM-DSS and in CRC cell line Caco2 formed xenograft models. Consistently, P. stomatis co-culture with CRC cells accelerated cell growth, induced G_1-S cell cycle progression, and suppressed apoptosis. FISH, TEM and in vitro adhesion/invasion assays showed that P. stomatis colonized on CRC cells and colonic epithelium cells of mice, with preferential adherence in tumor cells compared to normal colon cells. Mechanistically, P. stomatis surface protein fructose-1,6-bisphosphate aldolase (FBA) binds to integrin α6/β4 receptor of CRC cells and activates ERBB2 phosphorylation, leading to the consequential activation of MEK-ERK-p90 oncogenic signaling. Integrin α6/β4 knockdown abolished P. stomatis adherence and P. stomatis-induced ERBB2-MEK-ERK-p90 activation in vitro, implying that the FBA-integrin α6/β4 interaction is essential for P. stomatis-mediated tumorigenesis. Finally, we demonstrated that P. stomatis co-culture with colon cancer cell lines Caco-2 and HT-29 significantly abolished the therapeutic effects of Cetuximab and Vemurafenib, implying P. stomatis as a novel factor driving tyrosine kinase (RTK) inhibitor resistance through alternative activation of ERBB2 in CRC.

Conclusion: P. stomatis is a novel oncogenic bacterium in promoting colorectal carcinogenesis. P. stomatis surface protein FBA engages an integrin α6/β4-ERBB2 complex leading to aberrant activation of host oncogenic MEK-ERK-p90 signaling to drive CRC development and cause resistance to RTK inhibitors.

BACKGROUND & AIMS: Peptostreptococcus anaerobius is a pathogenic bacterium enriched in colorectal cancer (CRC) and it promotes colorectal tumorigenesis in mice. Here, we investigated the functional role of P. anaerobius in the tumor immune microenvironment (TIME) of CRC, the molecular basis of its action, and the consequential impact on the efficacy of immune checkpoint blockade (ICB) therapy.
METHODS: Immunomodulatory effects of P. anaerobius in Apc^Min/+, azoxymethane (AOM)- or AOM/ Dextran Sodium Sulfate (DSS)-treated CRC mouse models were investigated by single cell RNA-sequencing (scRNA-seq), flow cytometry and immunofluorescence staining. The effect of P. anaerobius on anti-PD-1 efficacy was evaluated in syngeneic mouse CRC cell line MC38 allograft and in AOM/DSS-induced CRC tumorigenesis in mice. Cytokine array was performed to identify chemokines produced by CRC cells upon P. anaerobius treatment. Immunomodulatory protein secreted by P. anaerobius was identified by mass spectrometry. Microscale thermophoresis and GST pull-down assay were used to identify corresponding receptor on MDSCs.
RESULTS: P. anaerobius significantly induced MDSCs accumulation, whilst suppressed IFNγ⁺CD8⁺T cells in colonic tumors of Apc^Min/+, which was confirmed in AOM-induced CRC and AOM/DSS-induced CRC mouse models by scRNA-seq, flow cytometry and immunofluorescence staining analyses. By fostering an immunosuppressive TIME, P. anaerobius administration abolished the efficacy of anti-PD-1 therapy both in MC38 allografts and in AOM/DSS-induced CRC tumorigenesis in mice. Mechanistically, P. anaerobius simultaneously promotes MDSCs recruitment and activation through a two-step pathway. Firstly, P. anaerobius co-culture promoted CXCL1 secretion by CRC cells via the integrin α₂/β₁-NF-κB axis. P. anaerobius-induced CXCL1 up-regulation in turn stimulated the migration of CXCR2⁺ MDSCs. Knockdown of integrin α₂/β₁or NF-κB inhibitor reversed P. anaerobius-induced CXCL1 secretion by CRC cells, accompanied by attenuated MDSCs chemotaxis. Secondly, P. anaerobius culture supernatant directly activated immunosuppressive function of intratumoral MDSCs. Mass spectrometry revealed a P. anaerobius secreted protein, LytC_22, which binds to SLAMF4 receptor on MDSCs to promote ARG1 and iNOS expression, thus enhancing the ability of MDSCs to inhibit cytotoxic T cell proliferation and function. Blockade of integrin α₂/β₁or Slamf4 receptor abrogated P. anaerobius-induced MDSCs trafficking and activation, and restored anti-PD-1 efficacy in CRC tumor models.
CONCLUSION: P. anaerobius provokes resistance to anti-PD-1 treatment in CRC by promoting MDSCs chemotaxis and activation, which in turn suppresses T cell activation. Targeting integrin α2/β1 or SLAMF4 receptor is a promising strategy to overcome P. anaerobius-induced anti-PD-1 resistance in CRC patients.

Background: Inflammatory Bowel Disease (IBD) is characterized by chronic, relapsing episodes of tissue-damaging inflammation in the gastrointestinal tract. Compelling evidence suggests that patients with IBD have higher chances of developing psychiatric comorbidities (e.g., anxiety and depression), further impairing their disease course and quality of life. The intestinal microbiota has been linked to the modulation of mood and anxiety. Moreover, intestinal bacterial composition and function are altered in patients with IBD. We hypothesized that the microbiota of patients with IBD contributes to the onset of psychiatric comorbidities.

Methods: We used the microbiota-humanized mouse model to test our hypothesis. Fecal samples from two patients with Crohn’s disease (CD) and one age-matched healthy control (HC) were used as microbiota sources to colonize adult germ-free NIH Swiss mice of both sexes. Three weeks after colonization, mice were submitted to a battery of behavioural tests to assess anxiety- and depression-like behaviours; light preference, step-down, open field, digging, marble burying, and tail suspension tests.

Results: Colonization with CD microbiota did not induce overt colonic inflammation as body weight and colon length were similar in HC and CD mice. Male CD mice spent less time in light and displayed increased immobility in the tail suspension test when compared with HC mice, suggestive of anxiety- and depression-like behaviour, respectively. Importantly, no alterations in overall locomotion were observed among the two groups of mice, ruling out sickness-like behaviour. Female CD mice showed increased latency to step down, indicative of anxiety-like behaviour. No changes were observed in the open field, digging, and marble burying tests for both sexes.

Conclusion: Our data show that human-derived microbiota from patients with CD induces changes in emotionality-related tests in a gnotobiotic mouse model, and this occurs in a sex-dependent manner. Future studies are needed to investigate the molecular mechanisms underlying these behavioural changes, to guide the development of novel microbiota-based therapies.

Background: The worldwide disease burden caused by rotavirus (RV) has been reduced by broad deployment of live attenuated RV vaccines. Such orally administered RV vaccines infect enterocytes resulting in elicitation of mucosal antibodies that lastingly protect against virulent RV strains. However, such RV vaccines frequently fail to elicit protective immunity, particularly in children in low-income countries. Such ineffectiveness associates with lack of fecal RV antigens and subsequently RV-specific antibodies following vaccination indicating that RV vaccine failure results from the vaccine virus failing to infect its host. We hypothesize that such RV vaccine failure may, in part, reflect that select microbes harbored in some hosts impede infection of RV vaccine viruses.
Aim: Examine the extent to which microbiomes of children not responding to RV vaccination might contribute to their RV vaccine failure phenotype.
Approach: Groups of germ-free mice were administered fecal microbial transplants (FMT) from Mexican children who had exhibited robust or minimal RV-specific antibodies following RV vaccination. Two weeks later, mice were subjected to RV vaccination. The extent of infection of the vaccine virus was assayed by measuring fecal RV antigen shedding days 0-15. Vaccine efficacy was determined by measuring fecal and serum RV-specific antibodies on days 14-28. Microbes associated with RV vaccine failure were assessed by 16S sequencing.
Results: Microbiome transplant recapitulated donor RV vaccine response phenotype. Specifically, mice receiving FMT from successfully vaccinated children exhibited copious fecal RV antigen shedding and high RV antibody titers in response to RV vaccination. Concomitantly, such mice were impervious to subsequent RV challenges. In contrast, mice receiving FMT from children who had not responded to RV vaccination exhibited only modest levels of RV antigen shedding and RV antibody generation in response to RV vaccination. Moreover, such mice remained prone to RV infection when later challenged with this virus. Microbiota analysis revealed that one microbe associating with RV vaccine failure in some FMT recipients was Clostridium perfringens. Oral administration of cultured C. perfringens to gnotobiotic mice partially recapitulated the RV vaccine non-responder phenotype.
Conclusion: Intestinal microbiota composition can dictate the extent to which RV vaccine viruses infect and thus elicit protective immunity in their host. C. perfringens may be one, perhaps of many, bacterial species harbored in the intestine of RV-vaccine non-responders that influences RV vaccine outcomes.

Background: A recent study found decreased levels of bacteria-derived hypoxanthine in stool from constipation predominant IBS (IBS-C) patients suggesting a potential role for hypoxanthine in regulating GI transit. Serotonin (5-HT) produced by enterochromaffin (EC) cells is an important regulator of GI transit, hence EC cells represent a potential target for bacterial products.

Aim: The aim of the study is to determine the effect of hypoxanthine on EC cell function and GI transit.

Methods: Germ free (GF) mice colonized with Enterococcus faecalis (7 days) were maintained in ISOcage™ system. Whole gut transit was assessed using automated gut transit setup via high-definition cameras to monitor appearance of red pellet following carmine red gavage. Stool hypoxanthine and serotonin (5-HT) were measured using colorimetric assay and ELISA, respectively. Ca²⁺ was measured using Fura-2AM (ratiometric) in QGP-1 cells (EC cell model), and T84 (colonocyte model). GCaMP5 was used to assess Ca²⁺in organoids from NeuroD1-cre;GCaMP5-tdTomato mice [labeled enteroendocrine cells (EEC)], ex vivo colon preparations with intact innervation from E2aCre:GCaMP6s mice (express GCaMP in all cells) and Tph1-CreERT2;GCaMP5g-tdTomato mice (labeled EC cells).

Results: GF mice colonized with hypoxanthine-producing E. faecalis exhibit significantly shorter transit time (281.4±18.61 vs. 414.4±27.64 min) and higher stool 5-HT level (1.48±0.44 vs. 0.64±0.07) compared to GF mice colonized with isogenic mutant with reduced hypoxanthine production E. faecalis^hyp- (n=7-9/group, t-test, P<0.05). As hypoxanthine increased stool 5-HT levels, we measured Ca²⁺ response to hypoxanthine in several EC cell models. Hypoxanthine evoked Ca²⁺ influx in QGP-1 cells, primary EECs and organoid-derived EECs, but not in T84 cells (Figure. 1). In an ex vivo colon preparation from Tph1-CreERT2;GCaMP5g-tdTomato mice, luminal application of hypoxanthine evoked Ca²⁺ response (29.9±1.4 ΔF/F) in 43% of KCl-responding EC cells compared to 13% KCl-responding EC cells with spontaneous activity (14.9±2.0 ΔF/F; t-test, P<0.05; Figure. 2). Luminal application of hypoxanthine in ex vivo colon preparations from E2a-Cre;GCaMP6s mice (n=4) activated a subset of epithelial cells (~2 sec), and this was followed by robust activity in myenteric neurons (4-8 sec; t-test, P<0.05) and movement of the imaging field indicative of contractile activity.

Conclusion: Bacteria-produced hypoxanthine accelerates GI transit and increases 5-HT release from EC cells which may activate myenteric neurons and contractile activity. Our findings will facilitate the development of novel microbial therapies that target a distinct mechanism underlying IBS-C pathophysiology. <div id="gtx-trans" style="position: absolute; left: 204px; top: 530.562px;"> <div class="gtx-trans-icon"> </div> </div>

Background: Emerging evidence suggested gut microbiota as a key player in dictating cancer immunotherapy response. We previously demonstrated that Lactobacillus gallinarum, a probiotic species depleted in colorectal cancer (CRC) patients compared to healthy controls, inhibited CRC tumorigenesis. Beyond the cancer-protective effect, we aim to explore the immunomodulatory effect of L. gallinarum and its role in improving anti-PD1 efficacy in CRC.
Methods: The effect of L. gallinarum and its generated metabolite in modulating anti-PD1 response was assessed in syngeneic mouse models and azoxymethane (AOM)/dextran sulphate sodium (DSS)-induced CRC tumorigenesis model. The change of immune landscape was identified by multicolor flow cytometry, which was validated by immunohistochemistry staining and in vitro functional assays. Metabolomic profiling was performed by liquid chromatography mass spectrometry to identify the functional metabolites.
Results: L. gallinarum significantly improved anti-PD1 efficacy in two syngeneic mouse models with different microsatellite instability (MSI) status (MSI-high for MC38 model, MSI-low for CT26 model). It was further validated in AOM/DSS-induced tumorigenesis model, in which L. gallinarum sensitized mice to anti-PD1 therapy and significantly reduced tumor number and load. L. gallinarum synergized with anti-PD1 therapy by reducing intratumoral infiltration of Foxp3+ CD25+ regulatory T cells (Treg), and enhancing effector function of CD8⁺ T cells. The metabolite indole-3-carboxylic acid (ICA) were enriched in serum of L. gallinarum-treated mice, suggesting its potential role in modulating antitumor immunity. RNA sequencing of tumor tissues from L. gallinarum-treated mice revealed a downregulation of tryptophan metabolism pathway. We confirmed that L. gallinarum and its derived ICA inhibited indoleamine 2,3-dioxygenase (IDO1) expression in tumors, thus suppressed the conversion of tryptophan to kynurenine (Kyn), a host-derived metabolite that promotes tumor progression and immune evasion. Moreover, ICA competed with Kyn for aryl hydrocarbon receptor (AHR) binding on CD4+ Treg cells. Owing to its higher receptor affinity, ICA displaced Kyn from AHR and therefore inhibited Kyn-mediated Treg differentiation in vitro. ICA phenocopied L. gallinarum effect and significantly improved anti-PD1 efficacy in CT26 subcutaneous tumor model. ICA reduced Treg infiltration, improved effector function of CD8+ T cells and suppressed Kyn production in vivo, which could be reversed by Kyn supplementation.
Conclusion: L. gallinarum and its derived ICA improved anti-PD1 efficacy in CRC by reducing Treg infiltration and enhancing effector function of CD8+ T cells through modulating the IDO1/Kyn/AHR metabolic axis. L. gallinarum may be leveraged as a potential adjuvant to augment anti-PD1 efficacy against CRC.

Background: The gut microbiome produces dozens of drug-like small molecules that bind host receptors and improve intestinal health. This is attracting attention as a new drug discovery target for inflammatory bowel disease and other intestinal disorders. However, the greatest barrier to such drug development is that most of the microbial genes which produce beneficial metabolites are unknown. Defining genes responsible for bacterial metabolite production is typically a slow serial process of gene prediction, targeted mutation, and phenotype testing. To overcome these limitations, we developed a new unbiased method for discovering genes that encode metabolic pathways at scale. Method: Clostridium sporogenes, one of the most metabolically versatile gut commensal bacteria, was used as the first model bacterium. We implemented a mariner transposon mutagenesis system in this strictly anaerobic bacterium and used a colony picking robot to isolate ~10,000 individual transposon mutants (Figure 1A). We then developed a new high-throughput liquid chromatography-mass spectrometry (LC-MS) assay to quantify >30 metabolites in less than 5 minutes per sample (Figure 1B). Mutants with significant metabolic phenotypes were genotyped using arbitrarily primed PCR (Figure 1C). Results: By sequencing ~320 randomly chosen transposon mutants, we found that transposon insertion is evenly distributed across the bacterial chromosome (Figure 1D). We applied this LC-MS platform to ~6,000 transposon mutants and identified over 200 genes as being responsible for the metabolism of microbial metabolites. These genes fell into three categories: 1) genes likely involved in housekeeping functions manifesting pleiotropic effects on multiple metabolites, 2) genes known to be involved in pathways for drug-like small molecules, and 3) novel genes which we have now genetically linked to specific metabolic pathways. Conclusion: We developed a new approach that can identify microbial genes responsible for microbial metabolites at a genome-wide scale. This work will facilitate our understanding of the mechanisms by which the microbiome influences human intestinal health to advance drug discovery.

Dylan Dodd

Appearances